CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  • The CHMP recommended approval of ELZONRIS for the first line treatment of adult patients with BPDCN
  • If approved by the European Commission, ELZONRIS will be the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, in Europe
123578910Last
Scroll Top